September 24, 2025
Gesorela and Sotorasib are like two different guardian angels. While both protect health, they have distinct missions.
Sotorasib is like a precise key, specifically designed for the specific KRAS G12C gene mutation. It received approval in 2021 and has helped many patients with non-small cell lung cancer.
Gesorela, like a gentle new friend, is slowly coming into our view. It is still undergoing clinical trials and is expected to be officially released in 2025, bringing new hope to patients with solid tumors harboring specific gene mutations.
The two drugs inhibit tumor growth through different molecular mechanisms. Sotorasib irreversibly binds to the KRAS G12C protein, locking it in an inactive state and thereby suppressing tumor cell proliferation signals.
Gesorela, on the other hand, uses a dual inhibitory mechanism, simultaneously targeting multiple signaling pathways to inhibit tumor growth and metastasis. More detailed clinical data on the specific mechanism of action will be released after the drug is officially launched.
Sotorasib is available in several versions: the original drug, Lumakras (manufactured by Amgen, USA), has a strength of 240 120mg tablets and a price of approximately US$8,500; the generic version, manufactured by BDR Pharmaceuticals in India, has a strength of 120mg tablets and a price of approximately US$2,200; and the generic version, manufactured by Everest Pharmaceuticals in Bangladesh, has a strength of 120mg tablets and a price of approximately US$1,950.
The original drug, Gexorexel, is expected to be available in a strength of 90 80mg tablets upon launch, with a potential price of approximately US$7,200. Generic versions are expected to be released 6-8 months after the original drug's launch.
Important: Genetic testing is required before using both drugs. Sotorasib requires testing for the KRAS G12C mutation, while Gexorexel requires testing for specific gene mutation types (specific details to be determined in the drug package insert).
We can provide professional genetic testing services to help determine your suitability for these targeted drugs. Our medical specialists will provide you with personalized medication recommendations based on the test results.
When choosing a medication, you should consider a comprehensive range of factors, including genetic test results, disease stage, physical condition, and financial considerations. We recommend that you select the most appropriate treatment plan based on the specific genetic mutation and condition under the guidance of a professional physician.
Regular monitoring of medication efficacy and adverse reactions is necessary during treatment, allowing for timely adjustments to the treatment plan. We provide comprehensive medication guidance, including adverse reaction management and medication effectiveness evaluation.
